<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02100670</url>
  </required_header>
  <id_info>
    <org_study_id>202179</org_study_id>
    <secondary_id>RH01805</secondary_id>
    <nct_id>NCT02100670</nct_id>
  </id_info>
  <brief_title>A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain</brief_title>
  <official_title>A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase III pivotal efficacy study will assess efficacy and onset of pain relief of
      MFC51123 gel vs. placebo and MFC51123 gel vs. 1% diclofenac gel and 3% menthol gel in
      participants with an ankle sprain to support topical MFC51123 gel registration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, repeat-dose, placebo-controlled,
      parallel-group trial in participants with ankle sprain. Eligible participants will be
      randomly assigned to one of four treatment groups (1% diclofenac plus 3% menthol gel, 1%
      diclofenac plus 0.09% menthol gel, 3% menthol gel or placebo gel with 0.09% menthol).
      Treatment will be self-administered by participants four times daily on an out-patient basis.
      Participants will rate pain intensity score (NRS) at rest and on movement, pain relief score
      (PRS) and cooling and soothing sensations. After leaving the clinic, participants will
      continue to complete scheduled pain intensity and pain relief assessments and answer
      questions about cooling sensation by answering questions in a paper diary card. The
      investigator (or designee) will measure the ankle swelling via the 'figure-of-eight' method
      on treatment Days 1 (at Baseline), 3, 7 and 10.

      Participants will continue treatment until they are pain free or for up to 10 days, whichever
      occurs first. At the end of the treatment, participants will be assessed for function of the
      injured joint by the investigator. In addition, the participants will evaluate treatment
      satisfaction, sensory features of the gel and provide a global assessment of the treatment by
      using a questionnaire.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1, 2013</start_date>
  <completion_date type="Actual">March 22, 2015</completion_date>
  <primary_completion_date type="Actual">March 1, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference (PID) on Movement</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.
Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PID at Rest</measure>
    <time_frame>Baseline to 10 days</time_frame>
    <description>PID at rest was calculated as PI at a given time point't' (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).
PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Score (PRS)</measure>
    <time_frame>Day 1 to Day 7</time_frame>
    <description>Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Difference (SPID)</measure>
    <time_frame>Baseline to Day 7</time_frame>
    <description>SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Onset of Pain Relief (TOPR)</measure>
    <time_frame>Baseline to 10 days (end of study)</time_frame>
    <description>TOPR was measured by time when participants reported PRS ≥ 1, i.e. a &quot;little&quot; or &quot;perceptible&quot; pain relief'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Onset of Meaningful Pain Relief (TOMR)</measure>
    <time_frame>up to 10 days (end of study)</time_frame>
    <description>TOMR was measured by time when participants reported PRS ≥ 2, i.e. &quot;some&quot; or &quot;meaningful&quot; pain relief</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Onset of Cooling Sensation (TOCS)</measure>
    <time_frame>up to 6 hours</time_frame>
    <description>Time of onset of cooling sensation measured by time when subjects reported to have a 'cooling effect as an enhancement of pain relief'. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose &quot;Do you feel a cooling sensation at the injured ankle from the study gel?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Pain Relief (TOTPAR)</measure>
    <time_frame>Baseline to 168 hours</time_frame>
    <description>TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Temperature</measure>
    <time_frame>At 10, 30, 60 minutes, 4 and 6 hours</time_frame>
    <description>Skin temperature was measured by thermal imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Swelling</measure>
    <time_frame>Day 1 (baseline), 3, and 7</time_frame>
    <description>Ankle swelling measured by &quot;figure of eight&quot; method of injured ankle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Recovery</measure>
    <time_frame>up to 240 hours</time_frame>
    <description>Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment in Response to Treatment (PGART)</measure>
    <time_frame>up to Day 10</time_frame>
    <description>PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1% diclofenac sodium plus 3% menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% diclofenac sodium plus 0.09% menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% menthol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with 0.09% menthol gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each subject to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% diclofenac sodium plus 3% menthol</intervention_name>
    <description>To be applied four times daily for 10 days.</description>
    <arm_group_label>1% diclofenac sodium plus 3% menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% diclofenac sodium plus 0.09% menthol</intervention_name>
    <description>To be applied four times daily for 10 days.</description>
    <arm_group_label>1% diclofenac sodium plus 0.09% menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% menthol</intervention_name>
    <description>To be applied four times daily for 10 days.</description>
    <arm_group_label>3% menthol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo with 0.09% menthol gel</intervention_name>
    <description>To be applied four times daily for 10 days.</description>
    <arm_group_label>Placebo with 0.09% menthol gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 16-65 years

          -  Good general and mental health

          -  Grade I or Grade II acute sprain of the lateral ankle within 24 hours of Visit 1, a
             pain intensity score of the ankle sprain that is ≥ 5 as measured on an 11-point
             numerical rating scale, and a peri-malleolar edema (sub-malleolar perimeter difference
             of ≥ 20mm between injured and uninjured ankle

          -  Females of child-bearing age practicing a reliable method of contraception

        Exclusion Criteria:

          -  Pregnant or breast-feeding females

          -  If participant has treated the ankle sprain with treatment such as oral or other
             topical pain relief medications, massage or physical therapy since experiencing the
             ankle sprain

          -  Acute or chronic pain disorders, which may confound the study pain evaluations

          -  Participant has has injury to both ankles or to both medial and lateral ligaments of
             the same ankle

          -  Known or suspected hypersensitivity, allergy, intolerance or contraindication to the
             use of any of the study medications

          -  Participant has a medical history of renal or hepatic disease, a current active peptic
             ulcer or a history of upper gastrointestinal bleeding or perforation related to
             previous NSAID therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL International - Sites in Germany</name>
      <address>
        <city>Berlin</city>
        <zip>D-14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PAREXEL International, LLC</name>
      <address>
        <city>Berlin</city>
        <zip>D-14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pro scientia med im MARE Klinikum</name>
      <address>
        <city>Kiel</city>
        <zip>24119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2014</study_first_submitted>
  <study_first_submitted_qc>March 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <results_first_submitted>June 2, 2016</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 12, 2018</results_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at 16 centers in Germany.</recruitment_details>
      <pre_assignment_details>A total of 388 participants were screened, out of which 385 were randomized, 3 did not meet the study criteria. Of the 385 participants randomized, 360 participants completed the study, 25 did not complete the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1% Diclofenac Sodium+3% Menthol</title>
          <description>1% diclofenac sodium with 3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="P2">
          <title>1% Diclofenac Sodium</title>
          <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="P3">
          <title>3% Menthol</title>
          <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="113"/>
                <participants group_id="P3" count="78"/>
                <participants group_id="P4" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No swelling no pain</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 381 participants were included in safety population.</population>
      <group_list>
        <group group_id="B1">
          <title>1% Diclofenac Sodium+3% Menthol</title>
          <description>1% diclofenac sodium with 3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="B2">
          <title>1% Diclofenac Sodium</title>
          <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="B3">
          <title>3% Menthol</title>
          <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="77"/>
            <count group_id="B4" value="75"/>
            <count group_id="B5" value="381"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.4" spread="11.83"/>
                    <measurement group_id="B2" value="32.1" spread="11.40"/>
                    <measurement group_id="B3" value="33.8" spread="12.15"/>
                    <measurement group_id="B4" value="33.2" spread="11.63"/>
                    <measurement group_id="B5" value="32.8" spread="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel</title>
        <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
        <time_frame>up to 72 hours</time_frame>
        <population>Intent-to-Treat (ITT) population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium Plus (+) 3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo gel was supplied in 30g tubes for each participant to apply 4g of gel topically to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel</title>
          <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
          <population>Intent-to-Treat (ITT) population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>NRS Score (0 – 10 scale) * hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.97" spread="111.356"/>
                    <measurement group_id="O2" value="282.88" spread="100.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4144</p_value>
            <p_value_desc>P-value from multiple comparisons using t-test in Proc Mixed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least squares (LS) means from mixed model analysis of covariance with treatment, site as fixed effects, pain intensity at baseline as a covariates.</method_desc>
            <param_type>Difference of LS mean</param_type>
            <param_value>-9.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.45</ci_lower_limit>
            <ci_upper_limit>12.98</ci_upper_limit>
            <estimate_desc>Difference of LS mean of first named treatment minus second named treatment. Lower values of LS mean favours a better response because of lower pain intensity over time. 95% Confidence intervals of difference between LS means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo</title>
        <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
        <time_frame>up to 72 hours</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC1-3 Days of PI on Movement for Diclofenac Sodium + Methanol, Diclofenac, Methanol and Placebo</title>
          <description>AUC of PI on movement was measured by a numerical rating scale (NRS) during the 48 hour time interval from Day 1 to 3. AUC1-3 day was calculated based on trapezoidal method. Pain intensity was measured in NRS scale from 0 (no pain) to 10 (extreme pain). Participants assessed the severity of ankle pain using the NRS scale at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>NRS Score (0 – 10 scale) * hrs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.97" spread="111.356"/>
                    <measurement group_id="O2" value="261.11" spread="96.791"/>
                    <measurement group_id="O3" value="272.65" spread="118.196"/>
                    <measurement group_id="O4" value="282.88" spread="100.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8761</p_value>
            <p_value_desc>P-value from multiple comparisons using t-test in Proc Mixed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least squares (LS) means from mixed model analysis of covariance with treatment, site as fixed effects, pain intensity at baseline as a covariates.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.34</ci_lower_limit>
            <ci_upper_limit>21.50</ci_upper_limit>
            <estimate_desc>Difference of LS mean of first named treatment minus second named treatment. Lower values of LS mean favours a better response because of lower pain intensity over time. 95% Confidence intervals of difference between LS means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8164</p_value>
            <p_value_desc>P-value from multiple comparisons using t-test in Proc Mixed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least squares (LS) means from mixed model analysis of covariance with treatment, site as fixed effects, pain intensity at baseline as a covariates.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>2.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.46</ci_lower_limit>
            <ci_upper_limit>24.67</ci_upper_limit>
            <estimate_desc>Difference of LS mean of first named treatment minus second named treatment. Lower values of LS mean favours a better response because of lower pain intensity over time. 95% Confidence intervals of difference between LS means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9279</p_value>
            <p_value_desc>P-value from multiple comparisons using t-test in Proc Mixed</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least squares (LS) means from mixed model analysis of covariance with treatment, site as fixed effects, pain intensity at baseline as a covariates.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.27</ci_lower_limit>
            <ci_upper_limit>23.33</ci_upper_limit>
            <estimate_desc>Difference of LS mean of first named treatment minus second named treatment. Lower values of LS mean favours a better response because of lower pain intensity over time. 95% Confidence intervals of difference between LS means.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3442</p_value>
            <p_value_desc>P-value from multiple comparisons using t-test in Proc Mixed.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Least squares (LS) means from mixed model analysis of covariance with treatment, site as fixed effects, pain intensity at baseline as a covariates.</method_desc>
            <param_type>LS mean difference</param_type>
            <param_value>-10.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.26</ci_lower_limit>
            <ci_upper_limit>11.64</ci_upper_limit>
            <estimate_desc>Difference of LS mean of first named treatment minus second named treatment. Lower values of LS mean favours a better response because of lower pain intensity over time. 95% Confidence intervals of difference between LS means.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference (PID) on Movement</title>
        <description>PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.
Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
        <time_frame>Baseline to 10 days</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference (PID) on Movement</title>
          <description>PID on movement, calculated as PI at a given time 't' (after walking 5 steps on a flat surface) subtracted by the PI at baseline.
Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain). PI was measured at baseline (prior to treatment) and at 10, 30 minutes (min.) and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
          <units>score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PI at Baseline (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.55"/>
                    <measurement group_id="O2" value="7.4" spread="1.44"/>
                    <measurement group_id="O3" value="7.8" spread="1.60"/>
                    <measurement group_id="O4" value="7.7" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 10 min. (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="1.078"/>
                    <measurement group_id="O2" value="0.19" spread="0.855"/>
                    <measurement group_id="O3" value="0.29" spread="0.886"/>
                    <measurement group_id="O4" value="0.32" spread="1.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 30 min. (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="1.302"/>
                    <measurement group_id="O2" value="0.36" spread="0.967"/>
                    <measurement group_id="O3" value="0.49" spread="0.868"/>
                    <measurement group_id="O4" value="0.55" spread="1.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 1 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.348"/>
                    <measurement group_id="O2" value="0.50" spread="1.022"/>
                    <measurement group_id="O3" value="0.64" spread="1.146"/>
                    <measurement group_id="O4" value="0.64" spread="1.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 4 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="1.640"/>
                    <measurement group_id="O2" value="0.48" spread="1.057"/>
                    <measurement group_id="O3" value="0.79" spread="1.128"/>
                    <measurement group_id="O4" value="0.69" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 6 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.706"/>
                    <measurement group_id="O2" value="0.67" spread="1.094"/>
                    <measurement group_id="O3" value="0.91" spread="1.227"/>
                    <measurement group_id="O4" value="0.87" spread="1.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 12 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="1.692"/>
                    <measurement group_id="O2" value="0.99" spread="1.411"/>
                    <measurement group_id="O3" value="1.17" spread="1.542"/>
                    <measurement group_id="O4" value="0.95" spread="1.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 18 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="1.707"/>
                    <measurement group_id="O2" value="1.32" spread="1.409"/>
                    <measurement group_id="O3" value="1.44" spread="1.751"/>
                    <measurement group_id="O4" value="1.16" spread="1.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 24 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="1.866"/>
                    <measurement group_id="O2" value="1.58" spread="1.505"/>
                    <measurement group_id="O3" value="1.75" spread="1.808"/>
                    <measurement group_id="O4" value="1.53" spread="1.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 36 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="1.899"/>
                    <measurement group_id="O2" value="1.65" spread="1.592"/>
                    <measurement group_id="O3" value="1.55" spread="1.818"/>
                    <measurement group_id="O4" value="1.32" spread="1.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 48 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.914"/>
                    <measurement group_id="O2" value="2.01" spread="1.562"/>
                    <measurement group_id="O3" value="2.04" spread="1.874"/>
                    <measurement group_id="O4" value="1.92" spread="1.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 60 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="1.917"/>
                    <measurement group_id="O2" value="2.26" spread="1.659"/>
                    <measurement group_id="O3" value="2.56" spread="1.963"/>
                    <measurement group_id="O4" value="2.05" spread="1.888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 72 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.55" spread="1.989"/>
                    <measurement group_id="O2" value="2.42" spread="1.631"/>
                    <measurement group_id="O3" value="2.55" spread="1.977"/>
                    <measurement group_id="O4" value="2.28" spread="1.935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 84 hour (n=113, 107, 75, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.883"/>
                    <measurement group_id="O2" value="2.68" spread="1.686"/>
                    <measurement group_id="O3" value="3.08" spread="1.916"/>
                    <measurement group_id="O4" value="2.68" spread="2.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 96 hour (n=112, 107, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" spread="1.865"/>
                    <measurement group_id="O2" value="2.78" spread="1.890"/>
                    <measurement group_id="O3" value="3.03" spread="2.027"/>
                    <measurement group_id="O4" value="2.78" spread="1.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 108 hour (n=112, 107, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="1.980"/>
                    <measurement group_id="O2" value="3.01" spread="1.751"/>
                    <measurement group_id="O3" value="3.48" spread="1.989"/>
                    <measurement group_id="O4" value="3.18" spread="1.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 120 hour (n=111, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="1.864"/>
                    <measurement group_id="O2" value="3.17" spread="1.871"/>
                    <measurement group_id="O3" value="3.35" spread="2.044"/>
                    <measurement group_id="O4" value="3.14" spread="1.947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 132 hour (n=110, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" spread="1.961"/>
                    <measurement group_id="O2" value="3.53" spread="1.824"/>
                    <measurement group_id="O3" value="3.72" spread="1.913"/>
                    <measurement group_id="O4" value="3.47" spread="2.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 144 hour (n=110, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.76" spread="2.058"/>
                    <measurement group_id="O2" value="3.78" spread="1.870"/>
                    <measurement group_id="O3" value="3.68" spread="1.994"/>
                    <measurement group_id="O4" value="3.59" spread="1.979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 156 hour (n=109, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="2.115"/>
                    <measurement group_id="O2" value="4.05" spread="1.870"/>
                    <measurement group_id="O3" value="3.95" spread="1.999"/>
                    <measurement group_id="O4" value="3.88" spread="2.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 168 hour (n=105, 104, 73, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="2.103"/>
                    <measurement group_id="O2" value="4.11" spread="1.935"/>
                    <measurement group_id="O3" value="3.90" spread="2.122"/>
                    <measurement group_id="O4" value="3.95" spread="2.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 180 hour (n=105, 104, 73, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.58" spread="2.065"/>
                    <measurement group_id="O2" value="4.45" spread="1.980"/>
                    <measurement group_id="O3" value="4.37" spread="1.933"/>
                    <measurement group_id="O4" value="4.08" spread="2.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 192 hour (n=101, 102, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55" spread="2.081"/>
                    <measurement group_id="O2" value="4.59" spread="1.916"/>
                    <measurement group_id="O3" value="4.21" spread="2.197"/>
                    <measurement group_id="O4" value="4.22" spread="2.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 204 hour (n=101, 100, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="2.020"/>
                    <measurement group_id="O2" value="4.94" spread="1.984"/>
                    <measurement group_id="O3" value="4.87" spread="1.999"/>
                    <measurement group_id="O4" value="4.56" spread="2.122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 216 hour (n=95, 100, 69, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" spread="2.239"/>
                    <measurement group_id="O2" value="5.21" spread="2.100"/>
                    <measurement group_id="O3" value="4.87" spread="2.029"/>
                    <measurement group_id="O4" value="4.78" spread="1.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 228 hour (n=95, 100, 69, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="2.292"/>
                    <measurement group_id="O2" value="5.62" spread="2.068"/>
                    <measurement group_id="O3" value="5.28" spread="2.071"/>
                    <measurement group_id="O4" value="5.01" spread="2.113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 240 hour (n=32, 43, 22, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" spread="2.961"/>
                    <measurement group_id="O2" value="5.44" spread="2.196"/>
                    <measurement group_id="O3" value="5.41" spread="2.282"/>
                    <measurement group_id="O4" value="5.60" spread="1.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PID at Rest</title>
        <description>PID at rest was calculated as PI at a given time point’t’ (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).
PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
        <time_frame>Baseline to 10 days</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PID at Rest</title>
          <description>PID at rest was calculated as PI at a given time point’t’ (at rest) subtracted by the PI at baseline. Participants assessed the severity of ankle pain (PI) using the NRS scale from 0 (no pain) to 10 (extreme pain).
PI was measured at baseline (prior to treatment) and at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after dosing.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PI at Baseline (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="1.55"/>
                    <measurement group_id="O2" value="7.4" spread="1.44"/>
                    <measurement group_id="O3" value="7.8" spread="1.60"/>
                    <measurement group_id="O4" value="7.7" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 10 min. (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="1.146"/>
                    <measurement group_id="O2" value="0.43" spread="1.145"/>
                    <measurement group_id="O3" value="0.17" spread="0.715"/>
                    <measurement group_id="O4" value="0.25" spread="1.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 30 min. (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="1.185"/>
                    <measurement group_id="O2" value="0.45" spread="1.314"/>
                    <measurement group_id="O3" value="0.32" spread="0.818"/>
                    <measurement group_id="O4" value="0.44" spread="1.328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 1 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.283"/>
                    <measurement group_id="O2" value="0.62" spread="1.187"/>
                    <measurement group_id="O3" value="0.48" spread="0.940"/>
                    <measurement group_id="O4" value="0.41" spread="1.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 4 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.413"/>
                    <measurement group_id="O2" value="0.53" spread="1.115"/>
                    <measurement group_id="O3" value="0.66" spread="1.071"/>
                    <measurement group_id="O4" value="0.43" spread="1.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 6 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.473"/>
                    <measurement group_id="O2" value="0.62" spread="1.180"/>
                    <measurement group_id="O3" value="0.75" spread="1.183"/>
                    <measurement group_id="O4" value="0.53" spread="1.554"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 12 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="1.501"/>
                    <measurement group_id="O2" value="0.86" spread="1.432"/>
                    <measurement group_id="O3" value="0.90" spread="1.429"/>
                    <measurement group_id="O4" value="0.68" spread="1.535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 18 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="1.597"/>
                    <measurement group_id="O2" value="1.14" spread="1.482"/>
                    <measurement group_id="O3" value="1.10" spread="1.594"/>
                    <measurement group_id="O4" value="0.85" spread="1.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 24 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="1.579"/>
                    <measurement group_id="O2" value="1.39" spread="1.448"/>
                    <measurement group_id="O3" value="1.47" spread="1.535"/>
                    <measurement group_id="O4" value="1.13" spread="1.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 36 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.549"/>
                    <measurement group_id="O2" value="1.32" spread="1.490"/>
                    <measurement group_id="O3" value="1.22" spread="1.635"/>
                    <measurement group_id="O4" value="1.09" spread="1.787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 48 hour (n=117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.604"/>
                    <measurement group_id="O2" value="1.53" spread="1.464"/>
                    <measurement group_id="O3" value="1.51" spread="1.698"/>
                    <measurement group_id="O4" value="1.45" spread="1.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 60 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.603"/>
                    <measurement group_id="O2" value="1.83" spread="1.593"/>
                    <measurement group_id="O3" value="1.88" spread="1.747"/>
                    <measurement group_id="O4" value="1.64" spread="1.893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 72 hour (n= 117, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="1.776"/>
                    <measurement group_id="O2" value="1.91" spread="1.545"/>
                    <measurement group_id="O3" value="1.86" spread="1.782"/>
                    <measurement group_id="O4" value="1.76" spread="1.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 84 hour (n= 113, 107, 75, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="1.754"/>
                    <measurement group_id="O2" value="2.19" spread="1.655"/>
                    <measurement group_id="O3" value="2.19" spread="1.799"/>
                    <measurement group_id="O4" value="2.03" spread="1.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 96 hour (n= 112, 107, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" spread="1.790"/>
                    <measurement group_id="O2" value="2.17" spread="1.707"/>
                    <measurement group_id="O3" value="2.23" spread="1.721"/>
                    <measurement group_id="O4" value="2.00" spread="1.720"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 108 hour (n=112, 107, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.795"/>
                    <measurement group_id="O2" value="2.43" spread="1.833"/>
                    <measurement group_id="O3" value="2.48" spread="1.743"/>
                    <measurement group_id="O4" value="2.27" spread="1.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 120 hour (n= 111, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="1.836"/>
                    <measurement group_id="O2" value="2.48" spread="1.750"/>
                    <measurement group_id="O3" value="2.30" spread="1.856"/>
                    <measurement group_id="O4" value="2.09" spread="1.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 132 hour (n= 110, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="1.877"/>
                    <measurement group_id="O2" value="2.78" spread="1.819"/>
                    <measurement group_id="O3" value="2.68" spread="1.873"/>
                    <measurement group_id="O4" value="2.49" spread="1.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 144 hour (n= 110, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="1.989"/>
                    <measurement group_id="O2" value="2.77" spread="1.789"/>
                    <measurement group_id="O3" value="2.59" spread="1.965"/>
                    <measurement group_id="O4" value="2.49" spread="1.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 156 hour (n= 109, 107, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="2.011"/>
                    <measurement group_id="O2" value="3.11" spread="1.755"/>
                    <measurement group_id="O3" value="2.77" spread="1.884"/>
                    <measurement group_id="O4" value="2.65" spread="2.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 168 hour (n= 105, 104, 73, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.08" spread="2.037"/>
                    <measurement group_id="O2" value="3.15" spread="1.805"/>
                    <measurement group_id="O3" value="2.75" spread="1.869"/>
                    <measurement group_id="O4" value="2.64" spread="2.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 180 hour (n= 105, 104, 73, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" spread="2.100"/>
                    <measurement group_id="O2" value="3.38" spread="1.871"/>
                    <measurement group_id="O3" value="2.95" spread="1.747"/>
                    <measurement group_id="O4" value="2.88" spread="2.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 192 hour (n= 101, 102, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="2.240"/>
                    <measurement group_id="O2" value="3.30" spread="2.067"/>
                    <measurement group_id="O3" value="2.90" spread="1.928"/>
                    <measurement group_id="O4" value="3.00" spread="2.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 204 hour (n= 101, 100, 71, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="2.250"/>
                    <measurement group_id="O2" value="3.61" spread="2.030"/>
                    <measurement group_id="O3" value="3.37" spread="1.853"/>
                    <measurement group_id="O4" value="3.21" spread="2.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 216 hour (n= 95, 100, 69, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.77" spread="2.372"/>
                    <measurement group_id="O2" value="3.87" spread="2.028"/>
                    <measurement group_id="O3" value="3.22" spread="2.306"/>
                    <measurement group_id="O4" value="3.26" spread="1.936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 228 hour (n= 95, 100, 69, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="2.348"/>
                    <measurement group_id="O2" value="4.02" spread="2.074"/>
                    <measurement group_id="O3" value="3.64" spread="2.000"/>
                    <measurement group_id="O4" value="3.53" spread="2.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PID at 240 hour (n= 32, 43, 22, 42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.94" spread="2.862"/>
                    <measurement group_id="O2" value="4.23" spread="2.010"/>
                    <measurement group_id="O3" value="3.36" spread="2.610"/>
                    <measurement group_id="O4" value="3.67" spread="2.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Score (PRS)</title>
        <description>Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment.</description>
        <time_frame>Day 1 to Day 7</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Score (PRS)</title>
          <description>Pain relief was measured at each time point using a 5-point Pain Relief Scale ranging from 0-4 while at rest (Where: 0- No pain relief; 1- A little or perceptible pain relief; 2- Meaningful pain relief; 3- A lot of relief; 4- Complete relief). Participants assessed the degree of ankle pain relief using the PRS scores at 10, 30 minutes and 1, 4, 6, 12, 18 and 24 hours after the first dose of treatment and twice daily after the first day of treatment.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population. n is number of participants analyzed for respective time point for this outcome.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 10 min. (n= 117, 111, 77, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.616"/>
                    <measurement group_id="O2" value="0.29" spread="0.609"/>
                    <measurement group_id="O3" value="0.32" spread="0.498"/>
                    <measurement group_id="O4" value="0.36" spread="0.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 30 min. (n=117, 111, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.635"/>
                    <measurement group_id="O2" value="0.36" spread="0.585"/>
                    <measurement group_id="O3" value="0.49" spread="0.599"/>
                    <measurement group_id="O4" value="0.44" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 1 hour (n=116, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.625"/>
                    <measurement group_id="O2" value="0.46" spread="0.599"/>
                    <measurement group_id="O3" value="0.57" spread="0.677"/>
                    <measurement group_id="O4" value="0.40" spread="0.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 4 hour (n= 115, 110, 74, 71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.626"/>
                    <measurement group_id="O2" value="0.45" spread="0.552"/>
                    <measurement group_id="O3" value="0.51" spread="0.579"/>
                    <measurement group_id="O4" value="0.49" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 6 hour (n= 109, 105, 70, 69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.603"/>
                    <measurement group_id="O2" value="0.54" spread="0.605"/>
                    <measurement group_id="O3" value="0.63" spread="0.618"/>
                    <measurement group_id="O4" value="0.45" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 12 hour (n= 77, 89, 53, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.591"/>
                    <measurement group_id="O2" value="0.72" spread="0.707"/>
                    <measurement group_id="O3" value="0.74" spread="0.684"/>
                    <measurement group_id="O4" value="0.62" spread="0.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 18 hour (n= 76, 78, 53, 57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.689"/>
                    <measurement group_id="O2" value="0.73" spread="0.715"/>
                    <measurement group_id="O3" value="0.83" spread="0.753"/>
                    <measurement group_id="O4" value="0.70" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 24 hour (n= 111, 105, 72, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.662"/>
                    <measurement group_id="O2" value="0.74" spread="0.680"/>
                    <measurement group_id="O3" value="0.90" spread="0.754"/>
                    <measurement group_id="O4" value="0.81" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 36 hour (n= 116, 112, 77, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.709"/>
                    <measurement group_id="O2" value="0.84" spread="0.705"/>
                    <measurement group_id="O3" value="0.88" spread="0.760"/>
                    <measurement group_id="O4" value="0.78" spread="0.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 48 hour (n= 116, 112, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.806"/>
                    <measurement group_id="O2" value="0.84" spread="0.651"/>
                    <measurement group_id="O3" value="0.99" spread="0.716"/>
                    <measurement group_id="O4" value="0.99" spread="0.846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 60 hour (n=115, 111, 77, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.780"/>
                    <measurement group_id="O2" value="1.00" spread="0.714"/>
                    <measurement group_id="O3" value="1.16" spread="0.745"/>
                    <measurement group_id="O4" value="0.96" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 72 hour (n= 114, 109, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.784"/>
                    <measurement group_id="O2" value="1.06" spread="0.743"/>
                    <measurement group_id="O3" value="1.16" spread="0.806"/>
                    <measurement group_id="O4" value="0.97" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 84 hour (n= 113, 106, 75, 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="0.810"/>
                    <measurement group_id="O2" value="1.00" spread="0.756"/>
                    <measurement group_id="O3" value="1.25" spread="0.737"/>
                    <measurement group_id="O4" value="1.11" spread="0.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 96 hour (n= 112, 106, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.823"/>
                    <measurement group_id="O2" value="1.03" spread="0.762"/>
                    <measurement group_id="O3" value="1.01" spread="0.830"/>
                    <measurement group_id="O4" value="1.09" spread="0.743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 108 hour (n= 111, 105, 75, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" spread="0.876"/>
                    <measurement group_id="O2" value="1.13" spread="0.809"/>
                    <measurement group_id="O3" value="1.28" spread="0.894"/>
                    <measurement group_id="O4" value="1.15" spread="0.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 120 hour (n= 111, 107, 74, 72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.918"/>
                    <measurement group_id="O2" value="1.14" spread="0.782"/>
                    <measurement group_id="O3" value="1.24" spread="0.904"/>
                    <measurement group_id="O4" value="1.10" spread="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 132 hour (n= 110, 107, 73, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="0.931"/>
                    <measurement group_id="O2" value="1.24" spread="0.878"/>
                    <measurement group_id="O3" value="1.34" spread="0.931"/>
                    <measurement group_id="O4" value="1.30" spread="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 144 hour (n= 110, 107, 74, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.015"/>
                    <measurement group_id="O2" value="1.21" spread="0.919"/>
                    <measurement group_id="O3" value="1.30" spread="0.947"/>
                    <measurement group_id="O4" value="1.27" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 156 hour (n= 109, 106, 74, 74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.011"/>
                    <measurement group_id="O2" value="1.30" spread="1.053"/>
                    <measurement group_id="O3" value="1.47" spread="0.968"/>
                    <measurement group_id="O4" value="1.32" spread="0.952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 168 hour (n= 105, 103, 73, 73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.026"/>
                    <measurement group_id="O2" value="1.31" spread="0.990"/>
                    <measurement group_id="O3" value="1.34" spread="1.003"/>
                    <measurement group_id="O4" value="1.40" spread="0.924"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Difference (SPID)</title>
        <description>SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief.</description>
        <time_frame>Baseline to Day 7</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Difference (SPID)</title>
          <description>SPID was calculated as the time weighted sum of pain intensity differences (PID) from 0 to 7 Days. PID was calculated as PI at a given time point 't' subtracted by the PI at baseline. PI was measured on NRS scale from 0 (no pain) to 10 (extreme pain). The possible range of SPID for 0-6 hours was from -60 to 60, for 0-12 hours was from -120 to 120, for 0-1 day was from -240 to 240, for 0-3 days was from -720 to 720, for 0-7 days was from -1680 to 1680. A higher value of SPID indicates greater pain relief.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="9.299"/>
                    <measurement group_id="O2" value="3.19" spread="5.862"/>
                    <measurement group_id="O3" value="4.72" spread="6.306"/>
                    <measurement group_id="O4" value="4.37" spread="8.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 0-12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.19" spread="18.788"/>
                    <measurement group_id="O2" value="9.13" spread="13.284"/>
                    <measurement group_id="O3" value="11.74" spread="14.675"/>
                    <measurement group_id="O4" value="10.05" spread="16.706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 0-1 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.01" spread="38.722"/>
                    <measurement group_id="O2" value="26.54" spread="28.497"/>
                    <measurement group_id="O3" value="30.91" spread="34.158"/>
                    <measurement group_id="O4" value="26.21" spread="34.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 1 to 3 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.54" spread="87.184"/>
                    <measurement group_id="O2" value="100.07" spread="71.085"/>
                    <measurement group_id="O3" value="104.26" spread="83.689"/>
                    <measurement group_id="O4" value="90.88" spread="82.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 0 to 7 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.12" spread="265.919"/>
                    <measurement group_id="O2" value="452.44" spread="244.488"/>
                    <measurement group_id="O3" value="464.96" spread="281.243"/>
                    <measurement group_id="O4" value="438.45" spread="287.369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Onset of Pain Relief (TOPR)</title>
        <description>TOPR was measured by time when participants reported PRS ≥ 1, i.e. a “little” or “perceptible” pain relief’.</description>
        <time_frame>Baseline to 10 days (end of study)</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Onset of Pain Relief (TOPR)</title>
          <description>TOPR was measured by time when participants reported PRS ≥ 1, i.e. a “little” or “perceptible” pain relief’.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.2" upper_limit="157.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.2" upper_limit="168.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.2" upper_limit="94.3"/>
                    <measurement group_id="O4" value="4.00" lower_limit="0.2" upper_limit="187.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5404</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4639</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5118</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Onset of Meaningful Pain Relief (TOMR)</title>
        <description>TOMR was measured by time when participants reported PRS ≥ 2, i.e. “some” or “meaningful” pain relief</description>
        <time_frame>up to 10 days (end of study)</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participants to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participants to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participants to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participants to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Onset of Meaningful Pain Relief (TOMR)</title>
          <description>TOMR was measured by time when participants reported PRS ≥ 2, i.e. “some” or “meaningful” pain relief</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.50" lower_limit="0.2" upper_limit="203.8"/>
                    <measurement group_id="O2" value="76.83" lower_limit="0.2" upper_limit="184.1"/>
                    <measurement group_id="O3" value="72.00" lower_limit="0.2" upper_limit="203.5"/>
                    <measurement group_id="O4" value="93.50" lower_limit="0.2" upper_limit="203.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6918</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.31</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2389</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.73</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9817</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to reach perceptible pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Onset of Cooling Sensation (TOCS)</title>
        <description>Time of onset of cooling sensation measured by time when subjects reported to have a ‘cooling effect as an enhancement of pain relief’. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose “Do you feel a cooling sensation at the injured ankle from the study gel?</description>
        <time_frame>up to 6 hours</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Onset of Cooling Sensation (TOCS)</title>
          <description>Time of onset of cooling sensation measured by time when subjects reported to have a ‘cooling effect as an enhancement of pain relief’. To assess this endpoint, participants were asked at 10, 30 minutes and at 1, 4, 6 hours post first dose “Do you feel a cooling sensation at the injured ankle from the study gel?</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.17" upper_limit="6.0"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0.17" upper_limit="6.0"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.17" upper_limit="6.0"/>
                    <measurement group_id="O4" value="0.17" lower_limit="0.17" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7003</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to cooling sensation. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9565</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.35</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to cooling sensation. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6216</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to cooling sensation. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Pain Relief (TOTPAR)</title>
        <description>TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672.</description>
        <time_frame>Baseline to 168 hours</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Pain Relief (TOTPAR)</title>
          <description>TOTPAR was calculated as sum of the products of PRS with time interval from one time point to the other. PRS was measured at each time point on a scale: 0= No pain relief, 1= A little or perceptible pain relief, 2= Meaningful pain relief, 3= A lot of relief, 4= Complete relief. The possible range of TOTPAR for 0-6 hours was from 0 to 24, for 0-12 hours was from 0 to 48, for 0-24 hours was from 0 to 96, for 0-72 hours was from 0 to 288, for 24-72 hours was from 0 to 192 and for 0-168 hours was from 0 to 672.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>PRS Score (0 – 4 scale)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="3.162"/>
                    <measurement group_id="O2" value="2.64" spread="2.902"/>
                    <measurement group_id="O3" value="3.27" spread="3.176"/>
                    <measurement group_id="O4" value="2.75" spread="3.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="6.125"/>
                    <measurement group_id="O2" value="6.81" spread="6.178"/>
                    <measurement group_id="O3" value="8.02" spread="7.045"/>
                    <measurement group_id="O4" value="6.35" spread="6.732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0- 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.04" spread="12.048"/>
                    <measurement group_id="O2" value="16.14" spread="12.479"/>
                    <measurement group_id="O3" value="18.85" spread="14.517"/>
                    <measurement group_id="O4" value="15.71" spread="13.146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.14" spread="37.867"/>
                    <measurement group_id="O2" value="61.24" spread="35.877"/>
                    <measurement group_id="O3" value="66.69" spread="40.360"/>
                    <measurement group_id="O4" value="58.75" spread="41.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.10" spread="29.344"/>
                    <measurement group_id="O2" value="45.11" spread="26.431"/>
                    <measurement group_id="O3" value="47.84" spread="29.102"/>
                    <measurement group_id="O4" value="43.04" spread="31.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-168 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.97" spread="98.838"/>
                    <measurement group_id="O2" value="170.73" spread="97.187"/>
                    <measurement group_id="O3" value="184.17" spread="102.787"/>
                    <measurement group_id="O4" value="174.00" spread="94.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Temperature</title>
        <description>Skin temperature was measured by thermal imaging.</description>
        <time_frame>At 10, 30, 60 minutes, 4 and 6 hours</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Temperature</title>
          <description>Skin temperature was measured by thermal imaging.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>degree celsius (°C)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At 10 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.69" spread="3.706"/>
                    <measurement group_id="O2" value="29.31" spread="2.610"/>
                    <measurement group_id="O3" value="29.92" spread="2.118"/>
                    <measurement group_id="O4" value="30.93" spread="2.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 30 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.26" spread="3.161"/>
                    <measurement group_id="O2" value="29.81" spread="2.595"/>
                    <measurement group_id="O3" value="30.50" spread="2.117"/>
                    <measurement group_id="O4" value="31.47" spread="3.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 60 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.64" spread="2.986"/>
                    <measurement group_id="O2" value="30.74" spread="2.781"/>
                    <measurement group_id="O3" value="30.22" spread="2.388"/>
                    <measurement group_id="O4" value="31.78" spread="3.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 240 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.52" spread="2.880"/>
                    <measurement group_id="O2" value="31.26" spread="2.981"/>
                    <measurement group_id="O3" value="31.15" spread="3.221"/>
                    <measurement group_id="O4" value="31.57" spread="2.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At 360 min.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.02" spread="2.951"/>
                    <measurement group_id="O2" value="31.53" spread="3.299"/>
                    <measurement group_id="O3" value="31.27" spread="3.925"/>
                    <measurement group_id="O4" value="32.07" spread="3.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ankle Swelling</title>
        <description>Ankle swelling measured by &quot;figure of eight&quot; method of injured ankle.</description>
        <time_frame>Day 1 (baseline), 3, and 7</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Ankle Swelling</title>
          <description>Ankle swelling measured by &quot;figure of eight&quot; method of injured ankle.</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.9" spread="57.77"/>
                    <measurement group_id="O2" value="573.6" spread="50.20"/>
                    <measurement group_id="O3" value="577.1" spread="55.35"/>
                    <measurement group_id="O4" value="576.1" spread="50.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="566.2" spread="57.03"/>
                    <measurement group_id="O2" value="566.9" spread="49.55"/>
                    <measurement group_id="O3" value="567.0" spread="56.48"/>
                    <measurement group_id="O4" value="565.4" spread="52.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558.3" spread="56.02"/>
                    <measurement group_id="O2" value="558.8" spread="46.37"/>
                    <measurement group_id="O3" value="558.4" spread="56.88"/>
                    <measurement group_id="O4" value="557.0" spread="50.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Complete Recovery</title>
        <description>Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam).</description>
        <time_frame>up to 240 hours</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Complete Recovery</title>
          <description>Time to complete recovery measured as the day with complete relief of ankle pain (Participant-rated NRS scores were 0 for pain intensity at rest and pain) and swelling (Participants did not have any apparent swelling nor experience any pain or limitation of movement of the injured ankle as determined by the Principal Investigator or designee during the course of an ankle exam).</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="77"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.00" lower_limit="17.0" upper_limit="240.0"/>
                    <measurement group_id="O2" value="240.00" lower_limit="48.2" upper_limit="240.0"/>
                    <measurement group_id="O3" value="240.00" lower_limit="53.2" upper_limit="240.0"/>
                    <measurement group_id="O4" value="240.00" lower_limit="145.5" upper_limit="240.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0408</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>5.70</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to complete pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4507</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>2.65</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to complete pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3150</p_value>
            <p_value_desc>P-value from chi-square test of survival analysis.</p_value_desc>
            <method>chi-square test of survival analysis</method>
            <param_type>Cox proportional hazard ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>2.61</ci_upper_limit>
            <estimate_desc>Cox proportional hazard ratio of survival time, i.e. time to complete pain relief. The 95% confidence intervals of cox proportional hazard ratio.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Assessment in Response to Treatment (PGART)</title>
        <description>PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent)</description>
        <time_frame>up to Day 10</time_frame>
        <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Diclofenac Sodium+3% Menthol</title>
            <description>1% diclofenac sodium+3% menthol gel was supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O2">
            <title>1% Diclofenac Sodium</title>
            <description>1% diclofenac sodium with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O3">
            <title>3% Menthol</title>
            <description>3% menthol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo with 0.09% methanol gel was supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Assessment in Response to Treatment (PGART)</title>
          <description>PGART was measured at the end of study in a scale from 0-4 (Where: 0- Poor; 1- Fair; 2- Good; 3- Very Good; 4- Excellent)</description>
          <population>ITT population included all participants who fulfilled all the study entry criteria, received the study treatment and had at least one post-baseline efficacy assessment. This analysis was conducted on ITT population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="75"/>
                <count group_id="O4" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Poor=0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0.948"/>
                    <measurement group_id="O2" value="13" spread="1.051"/>
                    <measurement group_id="O3" value="6" spread="1.040"/>
                    <measurement group_id="O4" value="9" spread="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair=1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good=2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Good=3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Excellent=4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 weeks of administration of investigational product</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1% Diclofenac Sodium Plus 3% Menthol</title>
          <description>1% diclofenac sodium plus 3% menthol gel supplied in 30 gram (g) tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="E2">
          <title>1% Diclofenac Sodium Plus 0.09% Menthol</title>
          <description>1% diclofenac sodium plus 0.09% menthol gel supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="E3">
          <title>3% Menthol</title>
          <description>3% menthol gel supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
        <group group_id="E4">
          <title>Placebo With 0.09% Menthol Gel</title>
          <description>Placebo with 0.09% menthol gel supplied in 30g tubes sufficient for each participant to apply 4g of gel to the injured ankle region four times daily for up to 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>APPLICATION SITE DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE DISCOLOURATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE VESICLES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>NECROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>PYODERMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SKIN ABRASION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ARTHROPOD STING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>MUSCLE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BONE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>EXOSTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BURNING SENSATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BLISTER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>SKIN EXFOLIATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>SKIN WRINKLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>RASH VESICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

